|
Press Releases
| |
|
Displaying releases:
1-15 | 16-30 | 31-45 | 46-60 | 61-75 | 76-90 | 91-105 | 106-120 | 121-135 | 136-150 | 151-165 | 166-180 | 181-194
|
| |
Feb-25-2010
|
PALATIN TECHNOLOGIES, INC. TO RAISE $2.6 MILLION DOLLARS IN REGISTERED DIRECT OFFERING |
| |
Feb-16-2010
|
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 |
| |
Feb-09-2010
|
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
|
| |
Dec-01-2009
|
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate |
| |
Nov-16-2009
|
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009 |
| |
Nov-12-2009
|
Palatin Technologies, Inc. To Report Fiscal Year 2010 First Quarter Results;
Teleconference and Webcast to be held on November 16, 2009 |
| |
Oct-28-2009
|
Palatin Technologies to Present at 8th Annual BIO Investor Forum
|
| |
Sep-29-2009
|
Palatin Technologies to Receive $5 Million from AstraZeneca
|
| |
Sep-15-2009
|
Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at
2009 Heart Failure Society of America Annual Meeting |
| |
Sep-08-2009
|
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 |
| |
Sep-04-2009
|
Palatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009 |
| |
Sep-03-2009
|
Palatin Technologies to Present at the Rodman & Renshaw
11th Annual Global Investment Conference |
| |
Aug-12-2009
|
Palatin Technologies, Inc. Reports Positive Bremelanotide Study;
Improved Safety Profile with Subcutaneous Administration
|
| |
Aug-12-2009
|
Palatin Technologies, Inc. To Raise $3.1 Million
In Registered Direct Offering
|
| |
Aug-04-2009
|
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate |
| |
 |
|
|
